

Anti-Complement component C3 (human)**Mouse monoclonal antibody**Subclass: IgG₁/k

CAT. NO.

HYB 005-01

Clone: 2 D8

SPECIFICITY	HYB 005-01 is specific for human C3.
IMMUNOGEN	C3 isolated from human plasma
TESTED APPLICATIONS	ELISA, WB
SPECIES REACTIVITY (POSITIVE)	Human
SPECIES REACTIVITY (NEGATIVE)	Not determined
EPITOPE SPECIFICITY	Epitope specificity differs from that of HYB 030-08 and HAV 003-05 but slightly overlap as determined by inhibition ELISA.

PRESENTATION

Content:	Available in 200 µL and 1 mL size. 1 mg/mL +/- 15%. See Certificate of Analysis for details.
Preparation:	Protein-A purified
Form:	Liquid
Solvent:	0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide
Storage:	4-8°C without exposure to light. No precautions necessary during handling.

APPLICATION	ELISA: HYB 005-01 reacts strongly with C3. A strong reaction is seen in ELISA with C3 directly coated onto the microtiter well, and also when tested in sandwich ELISA in combination with a polyclonal antibody against C3 (e.g. DAKO A 0062). WB: After SDS-PAGE, HYB 005-01 reacts with C3 in reduced as well as non-reduced forms.
TARGET	C3 is a key component of the complement system since classical and alternative activation pathways merge at the C3 activation step when C3 is split into C3a and C3b. The molecular mass of C3 is 185 kDa and it consists of two chains (110 kDa and 75 kDa) held together by disulfide bonds (1, 2).
REFERENCES	1. Law SKA, Reid KBM (1988) Complement. In: In Focus (Ed. Male D) IRL Press: Oxford. 2. Morley BJ and Walport MJ (2000) The Complement FactsBook. Academic Press, London, UK.

CONDITIONS

Unless otherwise marked, all products are for research use only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. For in vitro use or further manufacture only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics A/S be responsible for loss of profits or indirect consequential losses resulting from use of its products.